Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFβ-secreting CD8+ T cell suppressors

被引:106
作者
Hahn, BH [1 ]
Singh, RP [1 ]
La Cava, A [1 ]
Ebling, FM [1 ]
机构
[1] Univ Calif Los Angeles, Div Rheumatol, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
D O I
10.4049/jimmunol.175.11.7728
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lupus-prone (NZB x NZW)F-1 mice spontaneously develop elevated titers of anti-DNA Abs that contain T cell determinants in their V, regions. We have previously shown that tolerization with an artificial peptide based on these T cell determinants (pConsensus (pCons)) can block production of anti-DNA Abs and prolong survival of the mice. In this study, we show that this protection depends in part on the generation of peripheral TGF beta- and Foxp3-expressing inhibitory CD8(+) (Ti) cells. These CD8(+) Ti cells suppress anti-DNA IgG production both in vitro and in vivo and require up-regulated expression of both Foxp3 and TGF beta to exert their suppressive function, as indicated by microarray analyses, small interfering RNA inhibition studies, and blocking experiments. Additionally, CD8(+) Ti cells from pCons-tolerized mice were longer-lived suppressors that up-regulated expression of Bcl-2 and were more resistant to apoptosis than similar cells from naive mice. These data indicate that clinical suppression of autoinimunity after administration of pCons depends in part on the generation of CD8(+) Ti cells that suppress secretion of anti-DNA Ig using mechanisms that include Foxp3, TGF beta, and resistance to apoptosis.
引用
收藏
页码:7728 / 7737
页数:10
相关论文
共 31 条
  • [1] Effects of administration of monoclonal antibodies (anti-CD4 or anti-CD8) on the development of autoimmune diseases in (NZW x BXSB)F1 mice
    Adachi, Y
    Inaba, M
    Sugihara, A
    Koshiji, M
    Sugiura, K
    Amoh, Y
    Mori, SI
    Kamiya, T
    Genba, H
    Ikehara, S
    [J]. IMMUNOBIOLOGY, 1998, 198 (04) : 451 - 464
  • [2] Development of autoantibodies before the clinical onset of systemic lupus erythematosus
    Arbuckle, MR
    McClain, MT
    Rubertone, MV
    Scofield, RH
    Dennis, GJ
    James, JA
    Harley, JB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (16) : 1526 - 1533
  • [3] MODULATION OF SLE INDUCTION IN NAIVE MICE BY SPECIFIC T-CELLS WITH SUPPRESSOR ACTIVITY TO PATHOGENIC ANTI-DNA IDIOTYPE
    BLANK, M
    BENBASSAT, M
    SHOENFELD, Y
    [J]. CELLULAR IMMUNOLOGY, 1991, 137 (02) : 474 - 486
  • [4] EILAT D, 1988, J IMMUNOL, V141, P1745
  • [5] Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1-and CDR3-based peptides of a pathogenic autoantibody
    Eilat, E
    Zinger, H
    Nyska, A
    Mozes, E
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2000, 20 (04) : 268 - 278
  • [6] Vaccination with minigenes encoding VH-derived major histo compatibility complex class I-binding Epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus
    Fan, GC
    Singh, RR
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (06) : 731 - 741
  • [7] TGF-β induces Foxp3+T-regulatory cells from CD4+CD25-precursors
    Fu, S
    Zhang, N
    Yopp, AC
    Chen, DM
    Mao, MW
    Chen, D
    Zhang, HJ
    Ding, YZ
    Bromberg, JS
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (10) : 1614 - 1627
  • [8] Hahn BH, 2001, ARTHRITIS RHEUM-US, V44, P432, DOI 10.1002/1529-0131(200102)44:2<432::AID-ANR62>3.0.CO
  • [9] 2-S
  • [10] HAHN BH, 2002, DUBOIS LUPUS ERYTHEM, P87